This program is FREE, but pre-registration is required.

The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion

The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion
Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).
*This program is FREE, but pre-registration is required. Register Now!*

Agenda:
8:30 – 8:35 a.m. - Welcome
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

8:35 – 8:45 a.m. - Pre-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

Session I
8:45 – 9:05 a.m. - Identification of High-Risk Disease and Initial Management of Biochemical Recurrence
Stephen Boorjian, MD

9:05 – 9:25 a.m. - Imaging of Advanced Prostate Cancer and Impact on Cancer Management
Kelly Stratton, MD

9:25 – 9:40 a.m. - M0 CRPC: Treatment Options and Goals of Therapy
Michael S. Cookson, MD

9:40 – 10:30 a.m. - Case-based Roundtable Discussions: Recurrent and nonmetastatic CRPC
• Case #1 –BCR & Novel PET Imaging– Stephen Boorjian, MD
• Case #2 – M0 CRPC – Michael S. Cookson, MD
Roundtable Discussants: All Faculty

10:30 – 10:45 a.m. - Break

10:45 – 11:05 a.m. - Manipulating the Androgen Axis: New Agents in mHSPC and CRPC
David F. Jarrard, MD

11:05 – 11:25 a.m. - Genetic Testing in Advanced Prostate Cancer
Leonard Gomella, MD

11:25 – 11:45 a.m. - mHSPC: Maximal Androgen Targeted vs Chemohormonal Therapy for mHSPC and Management of Oligometastatic Disease
David F. Jarrard, MD & Joshua Lang, MD

11:45 a.m. – 1:00 p.m. - Non-CME Lunch Symposia

Session II
1:00 – 1:20 p.m. - Bone Health and Radionuclide Therapy
Stephen Boorjian, MD

1:20 – 1:40 p.m. - Role of Immunotherapy and PARP Inhibitors
Alicia Morgans, MD, MPH

1:40 – 2:30 p.m. - Case-based Roundtable Discussions: Chemotherapy-naïve metastatic CRPC
• Case #3 - Early M1 CRPC (Docetaxel vs. AR vs. Sipleucel-T) – Kelly Stratton, MD
• Case #4 - Advanced M1 CRPC (Docetaxel and Ra-223) – Alicia Morgans, MD, MPH
Roundtable Discussants: All Faculty

2:30 – 2:45 p.m. - Break

Session III
2:45 – 3:10 p.m. - Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
Joshua Lang, MD

3:10 – 4:00 p.m. - Case-based Roundtable Discussions: Post-Chemotherapy metastatic CRPC
• Case #5 - Role of Genetic Testing in Advanced M1 CRPC (Immunotherapy or PARP Inhibitors) – Leonard Gomella, MD
• Case #6 - M1 CRPC Post-docetaxel, Neuroendocrine Cancer and End-of-Life Care – Joshua Lang, MD
Roundtable Discussants: All Faculty

4:00 p.m. - Adjourn
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD


Learning Objectives:

At the conclusion of this activity, participants will be able to:
PRACTICE GAP #1 (DISEASE STATE)
1. Describe the natural course of advanced prostate cancer from non-metastatic (M0) to metastatic hormone-sensitive disease (mHSPC), with progression to the development of castration-resistant disease (CRPC).
2. Describe the treatment options and outcomes for patients with biochemical recurrence after failed local therapy.
3. Identify available imaging and indications for use including next generation PET imaging in the assessment of men with biochemical recurrence after failed local therapy.
4. Describe the treatment options and outcomes for newly diagnosed mHSPC.
5. Explain the implications of CRPC on the management of both M0 and M1.
6. Discuss the molecular mechanisms and characterization of CRPC.
7. Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, metastatic prostate cancer and CRPC.

PRACTICE GAP #2 (GUIDELINES)
8. Discuss specific recommendations within the AUA Clinical Practice Guidelines.
9. Define M0 CRPC and the treatment options.
10. Discuss clinically meaningful endpoints in clinical trials of patients with M0 CRPC.
11. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
12. Discuss challenges in incorporating AUA Guidelines and management of advanced mHSPC and CRPC into community practice.

PRACTICE GAP #3 (ANDROGEN AXIS)
13. Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
14. Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
15. Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.
16. Discuss new uses for androgen axis agents in M0 CRPC.

PRACTICE GAP #4 (CHEMOTHERAPY, IMMUNOTHERAPY, PARP INHIBITORS AND CO-MORBIDITY)
17. Identify approved chemotherapeutics, immunotherapy and PARP Inhibitors for mCRPC.
18. Describe indications and contraindications for chemotherapy, immunotherapy and PARP Inhibitors in patients with mCRPC.
19. Identify co-morbid states and recognize their impact on treatment options for mCRPC.
20. Identify germline and somatic mutations and implications for treatment in mCRPC including indications for PAPR Inhibitors and pembrolizumab.
21. Discuss treatment sequencing in the advanced, metastatic and CRPC disease state.

PRACTICE GAP #5 (BONE HEALTH AND RADIONUCLIDE THERAPY)
22. Integrate advances in bone health management into patient-specific care plans.
23. Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
24. Discuss known adverse events associated with androgen biosynthesis inhibitors and radionuclide therapy.

PRACTICE GAP #6 (PAIN MANAGEMENT AND PALLIATIVE CARE)
25. Assess and manage pain in patients with symptomatic mHSPC and mCRPC.
26. Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.
27. Review the role of palliative care and supportive services in the management of late stage CRPC.